MOUNTAIN VIEW, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 5:15 p.m. PST in San Francisco.
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation.
About IGM Biosciences, Inc.
IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer, infectious diseases and autoimmune and inflammatory diseases. IGM’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 binding sites. IGM also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology and immunology and inflammation targets. For more information, please visit www.igmbio.com.
Contact
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com
CHICAGO, IL / ACCESSWIRE / April 4, 2024 / The American College of Osteopathic Family…
WINNIPEG, MB / ACCESSWIRE / April 4, 2024 / Medicure Inc. ("Medicure" or the "Company")…
All resolutions presented by the Company have been adoptedPARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE…
LONDON, UK / ACCESSWIRE / April 4, 2024 / The UK is ‘in the grip…
Intuitive Health Opens 31st Location, Fourth with Presbyterian Healthcare ServicesPLANO, TX / ACCESSWIRE / April…
BELLEVUE, WAS / ACCESSWIRE / April 4, 2024 / Overlake Medical Center & Clinics has…